香港股市 將收市,收市時間:5 小時 26 分鐘
  • 恒指

    19,600.05
    +158.87 (+0.82%)
     
  • 國指

    6,712.35
    +59.40 (+0.89%)
     
  • 上證綜指

    3,202.31
    -10.22 (-0.32%)
     
  • 滬深300

    3,965.27
    -2.93 (-0.07%)
     
  • 美元

    7.7833
    +0.0097 (+0.12%)
     
  • 人民幣

    0.8957
    -0.0036 (-0.40%)
     
  • 道指

    33,596.34
    -350.76 (-1.03%)
     
  • 標普 500

    3,941.26
    -57.58 (-1.44%)
     
  • 納指

    11,014.89
    -225.05 (-2.00%)
     
  • 日圓

    0.0566
    +0.0001 (+0.21%)
     
  • 歐元

    8.1492
    +0.0126 (+0.16%)
     
  • 英鎊

    9.4500
    +0.0220 (+0.23%)
     
  • 紐約期油

    74.29
    +0.04 (+0.05%)
     
  • 金價

    1,785.20
    +2.80 (+0.16%)
     
  • Bitcoin

    17,055.81
    +3.07 (+0.02%)
     
  • CMC Crypto 200

    402.54
    +0.74 (+0.18%)
     

US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines

  • The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC: COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.

  • Croda will also invest up to $58 million.

  • The investment will be used to establish a new lipid facility in Lamar, Pennsylvania. Construction is expected to start later this year, with the new capacity anticipated in 2025.

  • The investment supports the expansion of Croda's portfolio, by creating a third manufacturing site for lipid systems, alongside Croda's existing Alabaster, Alabama, U.S. (Avanti) and Leek, U.K. capabilities.

  • The cooperative agreement is a joint award from the Biomedical Advanced Research and Development Authority (BARDA), and an arm of the U.S. Department of defense will join forces for preparedness for future health emergencies.

  • Financial Times writes that Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines were the first approved jabs to be made with mRNA technology.

  • The vaccines rely on bubbles of fat known as lipid nanoparticles to deliver genetic codes that teach the immune system to recognize the virus.

  • Lipid systems offer significant potential as the delivery system for many nucleic acid applications, including novel mRNA-based therapeutics, such as flu vaccines and cancer treatments.

  • Given the current clinical development pipeline's scale, the lipid systems market is expected to grow significantly over the next ten years.

  • Image by Spencer Davis from Pixabay

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.